Philogen S.p.A. Updates on Share Buyback Program

The latest update is out from Philogen SpA ( (IT:PHIL) ).

Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 1,887 shares between March 10 and March 14, 2025, at an average price of Euro 18.6538 per share, totaling Euro 35,199.73. This move is part of a broader strategy, with the company having acquired 34,984 shares since the program’s inception, reflecting its commitment to enhancing shareholder value and potentially signaling confidence in its market position.

More about Philogen SpA

Philogen S.p.A. is an Italian-Swiss biotechnology company specializing in the research and development of pharmaceutical products aimed at treating diseases with high mortality rates. The company focuses on creating targeted anti-cancer drugs using high-affinity ligands for tumor markers, primarily through monoclonal antibody-based ligands for vascular targeting. Philogen aims to generate innovative treatments for diseases lacking satisfactory therapies, leveraging proprietary technologies and a robust portfolio of patents.

YTD Price Performance: 3.68%

Average Trading Volume: 317

Technical Sentiment Consensus Rating: Sell

Current Market Cap: €552.7M

For a thorough assessment of PHIL stock, go to TipRanks’ Stock Analysis page.